Improving COVID interventions through diversity in clinical trials

AstaZeneca is joining a growing body of pharmaceutical development companies to realize the multifaceted value of decentralized, at-home medical trials. COVID has affected diverse populations around the world, yet the vast majority of clinical research and drug trials have taken place amongst white populations. 

Latin American man receives a shot in his left arm from a medical provider.

Increasing diversity in clinical trials is critical to understanding how various populations are affected by medical interventions. Running clinical trials in diverse locations also allows for faster access to treatments and improved outcomes for people in impoverished areas, and those with barriers to care. In-home trials overcome transportation and time constraints for participants, allowing a far broader group of participants to be included.  

Investing more deeply in decentralized clinical trials across Latin America is necessary and an invaluable tool for increasing diversity and representation of these populations in clinical data. H Clinical is committed to bringing participants and researchers together to LATAM countries to increase access to and diversity in clinical trials.

Read the article here:


We provide in-home health services for clinical trials across Latin America.

H Clinical is the leader in decentralized trial support in Latin America. H Clinical empowers sponsors to reach more patients and patients to participate from the comfort of home. Through an extensive network of GCP trained home health providers, logistics infrastructure, and clinical trial coverage from the Rio Grande to Patagonia, H Clinical is bringing clinical research home.